Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy

• Main Authors: Jingjing Su (Author), Yiting Fu (Author), Zitong Cui (Author), Zain Abidin (Author), Jingsong Yuan (Author), Xinmiao Zhang (Author), Runmin Li (Author), Chunzhen Zhao (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Relatlimab is a type of human immunoglobulin G4 monoclonal blocking antibody. It is the world's first Lymphocyte-Activation Gene-3 (LAG-3) inhibitor and the third immune checkpoint inhibitor with clinical application, following PD-1 and CTLA-4. Relatlimab can bind to the LAG-3 receptor which bl...